Uncategorized
FDA accepts application for ThromboGenics’ studyof Jetrea in nonproliferative diabetic retinopathy
The FDA has accepted ThromboGenics’ investigational new drug application for the phase 2 CIRCLE study of ocriplasmin to treat nonproliferative diabetic retinopathy, according to a press release.The randomized, double-masked, sham-controlled, multicenter study will evaluate the efficacy and safety of multiple doses of Jetrea (ocriplasmin) in inducing total posterior vitreous detachment in patients with moderate to severe nonproliferative diabetic retinopathy. The trial will be conducted in the U.S. and several countries in Europe, the release said.